Decheng Capital LLC Sells 64,485 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Decheng Capital LLC reduced its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 16.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 335,515 shares of the company's stock after selling 64,485 shares during the quarter. 4D Molecular Therapeutics makes up about 0.3% of Decheng Capital LLC's investment portfolio, making the stock its 22nd biggest holding. Decheng Capital LLC owned approximately 0.72% of 4D Molecular Therapeutics worth $1,084,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FDMT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of 4D Molecular Therapeutics by 7.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after buying an additional 2,925 shares during the period. ProShare Advisors LLC lifted its position in 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock worth $91,000 after purchasing an additional 3,783 shares during the period. American Century Companies Inc. lifted its position in 4D Molecular Therapeutics by 12.9% in the fourth quarter. American Century Companies Inc. now owns 38,785 shares of the company's stock worth $216,000 after purchasing an additional 4,429 shares during the period. Proficio Capital Partners LLC increased its holdings in shares of 4D Molecular Therapeutics by 26.0% in the first quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company's stock valued at $75,000 after buying an additional 5,195 shares in the last quarter. Finally, Nebula Research & Development LLC increased its holdings in shares of 4D Molecular Therapeutics by 37.4% in the fourth quarter. Nebula Research & Development LLC now owns 23,064 shares of the company's stock valued at $128,000 after buying an additional 6,277 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Trading Up 42.7%

NASDAQ:FDMT traded up $1.92 during mid-day trading on Friday, hitting $6.42. The company's stock had a trading volume of 31,473,829 shares, compared to its average volume of 360,319. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $17.41. The company has a market capitalization of $297.44 million, a price-to-earnings ratio of -2.02 and a beta of 2.83. The stock has a fifty day moving average of $4.21 and a 200-day moving average of $4.05.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

FDMT has been the topic of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Tuesday. The Goldman Sachs Group cut their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday. Finally, Barclays cut their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $29.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.